Therefore, we examined whether palbociclib-resistant NPC cells would remain vulnerable to cisplatin treatment and observed the acquisition of a new cell cycle pathway independent of RB phosphorylation (Fig. 6a). This evidence concerns the gene RB1 and nasopharyngeal carcinoma.